European Industrial Pharmacists Group

🌍 𝐄𝐈𝐏𝐆'𝐬 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐀𝐂𝐓 𝐄𝐔 𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐢𝐯𝐞: 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 EIPG, with Rebecca ⚕ Stanbrook, B.Pharm MRPharmS, FFRPS, Dip RQA, FRQA, is proud to be part of the 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 in the EU (ACT EU) initiative, launched by the #EMA and Heads of Medicines Agencies. #ACTEU is a game-changing initiative that aims to revolutionize clinical trials across Europe by fostering innovation, improving processes, and ensuring the 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐨𝐟 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲, 𝐬𝐚𝐟𝐞, 𝐚𝐧𝐝 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬. As part of the ACT EU 𝐌𝐮𝐥𝐭𝐢-𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 (MSP), EIPG actively contributes to the 𝐡𝐚𝐫𝐦𝐨𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐦𝐨𝐝𝐞𝐫𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 by facilitating dialogue among stakeholders, including patients, healthcare professionals, and academia. Our involvement aligns with ACT EU's priority actions, such as modernizing 𝐆𝐨𝐨𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐏𝐫𝐚𝐜𝐭𝐢𝐜𝐞 (GCP), supporting decentralized clinical trials, and enhancing collaboration to improve healthcare outcomes across Europe. By engaging in key meetings and workshops, such as the #MSP sessions held in June 2023 and March 2024, 𝐄𝐈𝐏𝐆 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐭𝐨 𝐩𝐥𝐚𝐲 𝐚 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞. As we look ahead, we remain committed to advancing 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧, 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧, 𝐚𝐧𝐝 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐟𝐥𝐞𝐱𝐢𝐛𝐢𝐥𝐢𝐭𝐲. 💡 Stay tuned for updates on upcoming meetings and EIPG’s ongoing contributions to this transformative journey. #ClinicalTrials #Pharmaceuticals #EIPG #HealthcareInnovation #DecentralisedTrials #GoodClinicalPractice #ClinicalResearch

EIPG is delighted to be an adhoc member of the ACT-EU MSP. We are looking forward to great discussions there, and future outcomes from this meeting.

📢 𝐓𝐡𝐞 𝐂𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐑𝐨𝐥𝐞 𝐨𝐟 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐢𝐧 𝐏𝐨𝐬𝐭-𝐏𝐚𝐧𝐝𝐞𝐦𝐢𝐜 𝐄𝐮𝐫𝐨𝐩𝐞 In relation to the shortage issue, EIPG reports a recent article about the 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐌𝐞𝐝𝐜𝐢𝐧𝐞𝐬 𝐟𝐨𝐫 𝐄𝐮𝐫𝐨𝐩𝐞. As Europe emerges from the pandemic, 𝐭𝐡𝐞 𝐠𝐞𝐧𝐞𝐫𝐢𝐜 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐡𝐚𝐬 𝐛𝐞𝐠𝐮𝐧 𝐭𝐨 𝐫𝐞𝐜𝐨𝐯𝐞𝐫, but significant challenges remain. Generics play a vital role in public health by providing essential medicines for serious conditions like cancer, cardiovascular diseases, diabetes, and infections. In fact, 𝐠𝐞𝐧𝐞𝐫𝐢𝐜𝐬 𝐚𝐜𝐜𝐨𝐮𝐧𝐭 𝐟𝐨𝐫 𝟕𝟎% 𝐨𝐟 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐝𝐢𝐬𝐩𝐞𝐧𝐬𝐞𝐝 𝐚𝐜𝐫𝐨𝐬𝐬 𝐄𝐮𝐫𝐨𝐩𝐞. However, the industry is facing hurdles such as rising energy costs and supply chain disruptions. High inflation, combined with downward pricing policies, is putting immense pressure on companies. This is leading to potential medicine shortages and reliance on outsourced production, which impacts the security of supply for essential medicines. 🎯 𝐖𝐡𝐚𝐭'𝐬 𝐍𝐞𝐞𝐝𝐞𝐝?  We need European-wide policy reform to ensure a 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐥𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐟𝐨𝐫 𝐠𝐞𝐧𝐞𝐫𝐢𝐜 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬. Pricing policies must adapt to rising production costs, and the industry requires new payment models that reflect the true value generics bring to public health. Medicines for Europe advocates for an EU Critical Medicines Act, which will safeguard the off-patent medicines sector and ensure security of supply. 🌍 It's time for coordinated action at the EU level 𝐭𝐨 𝐬𝐞𝐜𝐮𝐫𝐞 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐠𝐞𝐧𝐞𝐫𝐢𝐜𝐬 𝐚𝐧𝐝 𝐞𝐧𝐬𝐮𝐫𝐞 𝐞𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐟𝐨𝐫 𝐚𝐥𝐥 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧𝐬. Read the interview with Elisabeth Stampa, President of Medicines for Europe https://lnkd.in/gKcDDp5D   #Generics #PharmaInnovation #PublicHealth #MedicinesForEurope #HealthcareTransformation

Mario Draghi’s report describes 9 possible lines of action specifically targeted at the pharmaceutical sector #eipgeu #draghi #report #EU #pharma https://lnkd.in/dsj59Erm

EIPG looks very carefully at the impacts of new technologies, and in particular of 𝐚𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐢𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞, on the activity of #pharmacists and on the 𝐬𝐮𝐩𝐩𝐥𝐲 𝐜𝐡𝐚𝐢𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐰𝐨𝐫𝐥𝐝. 🔎 This reflection will be explored in depth in the #webinar which will investigate the 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐚𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐢𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐚𝐜𝐫𝐨𝐬𝐬 𝐭𝐡𝐞 𝐛𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐯𝐚𝐥𝐮𝐞 𝐜𝐡𝐚𝐢𝐧. A need also highlighted by EMA, which has published a 𝐫𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐩𝐚𝐩𝐞𝐫 𝐨𝐮𝐭𝐥𝐢𝐧𝐢𝐧𝐠 𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐭𝐡𝐢𝐧𝐤𝐢𝐧𝐠 𝐨𝐧 𝐭𝐡𝐞 𝐮𝐬𝐞 𝐨𝐟 𝐚𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐢𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 (𝐀𝐈) to support the safe and effective development, regulation and use of human and veterinary medicines. 📅 𝐒𝐀𝐕𝐄 𝐓𝐇𝐄 𝐃𝐀𝐓𝐄 𝐖𝐞𝐛𝐢𝐧𝐚𝐫 | 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐬𝐭 𝟓.𝟎 𝐞𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐚𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐢𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐝𝐫𝐢𝐯𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟔𝐭𝐡, 𝟏𝟕.𝟎𝟎 𝐂𝐄𝐓 ✏ Registrer for the webinar: https://lnkd.in/gfa_V9y8 #AI #artificalintelligence #pharma

🌍 EIPG has established a working group on 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐚𝐥 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 with the aim of exposing the contribution that the 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐚𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐬𝐭 can make to 𝐫𝐞𝐝𝐮𝐜𝐢𝐧𝐠 𝐭𝐡𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐢𝐞𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭. ✏ Any contribution is welcome! If you are interested, contact the EIPG delegate of your association. Visit our web site: https://www.eipg.eu/ #EIPG #sustainability #pharma

🚨 𝐓𝐡𝐞 𝐍𝐞𝐰 𝐄𝐔 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐃𝐮𝐞 𝐃𝐢𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐃𝐢𝐫𝐞𝐜𝐭𝐢𝐯𝐞 (𝐂𝐒𝐃𝐃𝐃) 🚨 On July 25, 2024, the Corporate Sustainability Due Diligence Directive (CSDDD) entered into force, marking a significant step in how companies across Europe (and beyond) must approach their supply chains. 🌍💼 What does it mean? This new regulation requires large companies to identify and address potential human rights violations and environmental impacts throughout their value chains—whether inside or outside the EU. The aim? To create a unified standard across Europe and reduce the fragmented regulatory landscape. 📊🌱 Key impacts: 🔸 Companies must adopt a due diligence process to assess risks, including upstream and downstream activities (suppliers, logistics, etc.). 🔸 Climate transition plans are now mandatory to align business strategies with the Paris Agreement. 🔸 Remedies are required if companies contribute to adverse impacts, with the possibility of terminating harmful business relationships as a last resort. ⚖️ Timeline: 2027: Companies with >5,000 employees or €1.5B turnover. 2028: Companies with >3,000 employees or €900M turnover. 2029: Companies with >1,000 employees or €450M turnover. Even smaller companies, although not directly targeted, may be indirectly affected if they fall within the supply chains of larger firms. 🌐 🌱 The Future is Sustainable 🌱 This directive is more than a regulation—it's a push toward more ethical and environmentally friendly business practices. The companies that adapt will not only comply but also lead in a more sustainable global economy. 🚀 #Sustainability #SupplyChain #CSR #HumanRights #EnvironmentalImpact #EUlaw #CorporateGovernance

While waiting for the programme of the new Commissioner for Innovation, several actions are undergoing to define the Horizon Europe Work Programme 2025 and the new Framework Programme FP10, due to be launched at the beginning of 2028 #eipgeu #eucommission #HorizonEU #FP10 https://lnkd.in/dVzh-YC4

📱 Validation of DTx 🧬 A recent study published in The Lancet Regional Health-Europe reveals that a smartphone application is three times more effective than traditional written materials in helping smokers quit. This groundbreaking research, conducted with 200 participants in a randomized controlled trial, underscores the potential of digital therapies (DTx) to deliver real, tangible health outcomes. 💡 However, as digital therapies grow in prominence, the debate on how to validate these technologies continues. While not all digital health tools require clinical trials, DTx, which target medical conditions, do need robust evidence to ensure their effectiveness and safety. The challenge? Some advocate for "digital exceptionalism," a notion that digital medicine may not need the same rigorous validation as traditional medicine. But without clear frameworks, this could jeopardize patient safety and hinder progress. 🏥 As Gualberto Gussoni of the Fondazione RIDE2Med warns: “We are dealing with therapeutic devices, and they must be held to the same high standards as drugs in terms of clinical validation, certification, and even reimbursement.” The road ahead involves not only global standards for efficacy but also considering local factors like user interface, which plays a crucial role in ensuring these digital therapies are effective for diverse populations. 🌍 Let's continue the conversation on how we can balance innovation with patient safety and clinical validation in the rapidly evolving field of digital health in the webinar organized by #Eipg 📅 𝐒𝐀𝐕𝐄 𝐓𝐇𝐄 𝐃𝐀𝐓𝐄 𝐖𝐞𝐝𝐧𝐞𝐬𝐝𝐚𝐲 𝟐𝐧𝐝 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 𝟏𝟕.𝟎𝟎 𝐂𝐄𝐒𝐓 (𝟏𝟔.𝟎𝟎 𝐁𝐒𝐓) Speaker : Giuseppe Recchia ✏️ Registration form : https://lnkd.in/eyNEAsHf #DigitalHealth #DTx #HealthcareInnovation #ClinicalTrials #AIinHealthcare #DigitalTherapies #HealthTech

📌𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐟𝐚𝐜𝐢𝐧𝐠 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 represent the emerging and most innovative area of 𝐡𝐞𝐚𝐥𝐭𝐡 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 for patients with chronic illnesses. Regarding this topic, EIPG organized a webinar with the aim of informing participants on how these new therapeutic technologies are developed and used.     📅 𝐒𝐀𝐕𝐄 𝐓𝐇𝐄 𝐃𝐀𝐓𝐄 𝐖𝐞𝐝𝐧𝐞𝐬𝐝𝐚𝐲 𝟐𝐧𝐝 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 𝟏𝟕.𝟎𝟎 𝐂𝐄𝐒𝐓 (𝟏𝟔.𝟎𝟎 𝐁𝐒𝐓) Speaker : Giuseppe Recchia, co-founder and CEO of DigitalRehab srl and daVi DigitalMedicine, startups involved in the research and development of patient-facing Digital Health Technologies   ✏️ Registration form: https://lnkd.in/eyNEAsHf